Fresenius Group Overview

Results Center

To archive

Q3/20 Results

Fresenius continues to demonstrate resilience amid the COVID-19 pandemic: FY/20 guidance confirmed given accelerated earnings growth in Q3

  • Fresenius Medical Care with continued strong earnings growth in constant currency
  • Fresenius Kabi showed a recovery in Europe and return to growth in China whilst headwinds weigh on North American business
  • Helios Germany with sales growth in Q3 due to recovery of elective procedures; Helios Spain with significant growth based on catch-up effects
  • Fresenius Vamed continues to be heavily impacted by COVID-19 related project delays, high-end technical service remained robust

Selected Key Figures Q3/20


1 In constant currency
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA